Advances in mouse models and human trials will continue to inform strategies for modulating TGF-β and neural pathways, offering hope for treatments targeting the metabolic and oncogenic consequences of obesity. This evidence concerns the gene TGFB1 and obesity due to melanocortin 4 receptor deficiency.